Perrigo Company plc OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax
Perrigo Company plc (PRGO) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax of $8.40 million for the 3-month period ending 2014-03-29, per its 10-Q filed 2014-05-07.
Discontinued › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax · last filed 2014-05-07
- Perrigo Company plc oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2014-03-29 was $8.40M.
| Period end | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 3 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 9 month |
|---|---|---|
| 2014-03-29 | $8.40M 10-Q · filed 2014-05-07 | $3.50M 10-Q · filed 2014-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |